English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

BeyondSpring Announces First Patient Enrolled in China in a Global Phase 3 Trial of Non-Small Cell Lung Cancer

Aug. 15, 2016

BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced on August 15, 2016 that the first patient in the global Phase 3 trial of its lead immuno-oncology asset Plinabulin, was enrolled in China.

Plinabulin is in a global Phase 3 trial in 2nd and 3rd line non-small cell lung cancer (NSCLC) in combination with docetaxel. This trial is being conducted in the U.S. and China and is expected to enroll 440 patients in China, and 110 patients in the U.S. and other western countries.